Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genentech Will Market OSI Cancer Drug In U.S. Under Three-Way Deal

Executive Summary

Genentech will market OSI Pharmaceuticals' anti-cancer drug OSI-774 in the U.S. under a three-way co-development and marketing deal between Genentech, Roche and OSI.

You may also be interested in...



Iressa Patients’ Lack Of Rash Suggests Dose Is Too Low For Benefit – OSI

Absence of rash in patients using AstraZeneca's Iressa suggests that the dose for the EGFR agent was not high enough to achieve clinical benefit, OSI Pharmaceuticals CEO Colin Goddard, PhD, said

Iressa Patients’ Lack Of Rash Suggests Dose Is Too Low For Benefit – OSI

Absence of rash in patients using AstraZeneca's Iressa suggests that the dose for the EGFR agent was not high enough to achieve clinical benefit, OSI Pharmaceuticals CEO Colin Goddard, PhD, said

Genentech Tarceva Trials “On Track” Despite INTACT: Response To Iressa

Genentech and OSI Pharmaceuticals are pointing to the dosing regimen in clinical trials of Tarceva (erlotinib) as one reason that Phase III studies of the EGFR oncologic agent will have a positive outcome despite the negative findings in AstraZeneca's Phase III program for Iressa

Related Content

UsernamePublicRestriction

Register

PS037184

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel